A virtual care program for outpatients diagnosed with COVID-19: a feasibility study.


Journal

CMAJ open
ISSN: 2291-0026
Titre abrégé: CMAJ Open
Pays: Canada
ID NLM: 101620603

Informations de publication

Date de publication:
Historique:
entrez: 25 5 2020
pubmed: 25 5 2020
medline: 25 5 2020
Statut: epublish

Résumé

In patients who are discharged home to self-isolate while coronavirus disease 2019 (COVID-19) test results are pending, there is no formal method for physician assessments or counselling to occur if the result returns positive. Our aim was to develop and test the feasibility of a virtual care program for self-isolating outpatients diagnosed with COVID-19. In preparation for this gap in health care, the COVID-19 Expansion to Outpatients (COVIDEO) program was developed at the Sunnybrook Health Sciences Centre, Toronto, Ontario, to provide ongoing care for outpatients diagnosed with COVID-19. As part of a feasibility study, we describe our experiences with the first 50 patients managed using this program from its inception (Mar. 1, 2020) until Mar. 27, 2020. All 50 people who tested positive for COVID-19 at the Sunnybrook Health Sciences Centre and were discharged home to self-isolation during the study period were assessed through the COVIDEO program. Thirty-two patients (64%) were assessed via the Ontario Telemedicine Network virtual care platform, and the remainder by telephone. The median time from viral swab collection to first COVIDEO program assessment was 2 (interquartile range [IQR] 1-2) days. Among the 26 patients for whom further follow-up care through the COVIDEO program was discontinued by the end of March 2020, the median duration of virtual care was 12.5 (IQR 8.75-16) days. During the study period, 6 patients required transfer to hospital for assessment, of whom 4 required admission. We have shown that a virtual care program can be used in the management of outpatients diagnosed with COVID-19. Further studies evaluating its sustainability and impact on health outcomes are underway.

Sections du résumé

BACKGROUND
In patients who are discharged home to self-isolate while coronavirus disease 2019 (COVID-19) test results are pending, there is no formal method for physician assessments or counselling to occur if the result returns positive. Our aim was to develop and test the feasibility of a virtual care program for self-isolating outpatients diagnosed with COVID-19.
METHODS
In preparation for this gap in health care, the COVID-19 Expansion to Outpatients (COVIDEO) program was developed at the Sunnybrook Health Sciences Centre, Toronto, Ontario, to provide ongoing care for outpatients diagnosed with COVID-19. As part of a feasibility study, we describe our experiences with the first 50 patients managed using this program from its inception (Mar. 1, 2020) until Mar. 27, 2020.
RESULTS
All 50 people who tested positive for COVID-19 at the Sunnybrook Health Sciences Centre and were discharged home to self-isolation during the study period were assessed through the COVIDEO program. Thirty-two patients (64%) were assessed via the Ontario Telemedicine Network virtual care platform, and the remainder by telephone. The median time from viral swab collection to first COVIDEO program assessment was 2 (interquartile range [IQR] 1-2) days. Among the 26 patients for whom further follow-up care through the COVIDEO program was discontinued by the end of March 2020, the median duration of virtual care was 12.5 (IQR 8.75-16) days. During the study period, 6 patients required transfer to hospital for assessment, of whom 4 required admission.
INTERPRETATION
We have shown that a virtual care program can be used in the management of outpatients diagnosed with COVID-19. Further studies evaluating its sustainability and impact on health outcomes are underway.

Identifiants

pubmed: 32447283
pii: 8/2/E407
doi: 10.9778/cmajo.20200069
pmc: PMC7252690
doi:

Types de publication

Journal Article

Langues

eng

Pagination

E407-E413

Informations de copyright

Copyright 2020, Joule Inc. or its licensors.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Cardiol. 2016 Nov;39(11):636-639
pubmed: 27701750
CMAJ. 2020 Mar 23;192(12):E314-E318
pubmed: 32144097
Telemed J E Health. 2013 May;19(5):373-6
pubmed: 23301768
Occup Med (Lond). 2008 May;58(3):226-7
pubmed: 18441368
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
BMJ. 2020 Mar 25;368:m1182
pubmed: 32213507
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524

Auteurs

Philip W Lam (PW)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont philip.lam@sunnybrook.ca.

Prateek Sehgal (P)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Nisha Andany (N)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Samira Mubareka (S)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Andrew E Simor (AE)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Omar Ozaldin (O)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Jerome A Leis (JA)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Nick Daneman (N)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Adrienne K Chan (AK)

Department of Medicine (Lam, Sehgal, Andany, Mubareka, Simor, Leis, Daneman, Chan), University of Toronto; Division of Infectious Diseases (Lam, Andany, Mubareka, Simor, Leis, Daneman, Chan), Sunnybrook Health Sciences Centre; Toronto Public Health (Ozaldin), Toronto, Ont.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH